|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5981216A
(en)
|
1985-04-01 |
1999-11-09 |
Alusuisse Holdings A.G. |
Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
GB8717430D0
(en)
|
1987-07-23 |
1987-08-26 |
Celltech Ltd |
Recombinant dna product
|
|
AU638734B2
(en)
|
1989-07-06 |
1993-07-08 |
Regents Of The University Of California, The |
Receptors for fibroblast growth factors
|
|
US5863888A
(en)
|
1990-07-06 |
1999-01-26 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Human Bek Fibroblast growth factor receptor
|
|
CA2103059C
(en)
|
1991-06-14 |
2005-03-22 |
Paul J. Carter |
Method for making humanized antibodies
|
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
|
US6323316B1
(en)
|
1996-06-18 |
2001-11-27 |
The United States Of America As Represented By The Secretary Of The Department Of And Human Services |
Fibroblast growth factor receptor activating gene 1 and related compositions and methods
|
|
PT994903E
(pt)
|
1997-06-24 |
2005-10-31 |
Genentech Inc |
Metodos e composicoes para glicoproteinas galactosiladas
|
|
EP1028751B1
(en)
|
1997-10-31 |
2008-12-31 |
Genentech, Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
|
EP1034298B1
(en)
|
1997-12-05 |
2011-11-02 |
The Scripps Research Institute |
Humanization of murine antibody
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
EP1068241B1
(en)
|
1998-04-02 |
2007-10-10 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
|
ES2434961T5
(es)
|
1998-04-20 |
2018-01-18 |
Roche Glycart Ag |
Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
|
|
WO2000025803A1
(en)
|
1998-10-30 |
2000-05-11 |
Takeda Chemical Industries, Ltd. |
Betacellulin protein-containing preparations
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
PT1176195E
(pt)
|
1999-04-09 |
2013-07-18 |
Kyowa Hakko Kirin Co Ltd |
Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
|
|
WO2000064946A2
(en)
|
1999-04-28 |
2000-11-02 |
Board Of Regents, The University Of Texas System |
Compositions and methods for cancer treatment by selectively inhibiting vegf
|
|
EP1229125A4
(en)
|
1999-10-19 |
2005-06-01 |
Kyowa Hakko Kogyo Kk |
PROCESS FOR PREPARING A POLYPEPTIDE
|
|
JP2001302699A
(ja)
|
2000-04-17 |
2001-10-31 |
Nichirei Corp |
ヒトｋｇｆｒに対する抗体
|
|
EP3263702A1
(en)
|
2000-10-06 |
2018-01-03 |
Kyowa Hakko Kirin Co., Ltd. |
Cells producing antibody compositions
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
|
IL159177A0
(en)
|
2001-06-20 |
2004-06-01 |
Prochon Biotech Ltd |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
|
RU2321630C2
(ru)
|
2001-08-03 |
2008-04-10 |
Гликарт Биотекнолоджи АГ |
Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
|
|
CN101357943A
(zh)
*
|
2001-10-25 |
2009-02-04 |
杰南技术公司 |
糖蛋白组合物
|
|
PL213948B1
(pl)
|
2001-10-25 |
2013-05-31 |
Genentech Inc |
Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
|
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
|
WO2003063893A2
(en)
|
2002-01-31 |
2003-08-07 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Fgfr agonists
|
|
US20040132101A1
(en)
*
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US8093357B2
(en)
*
|
2002-03-01 |
2012-01-10 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US7749753B2
(en)
|
2002-04-09 |
2010-07-06 |
Kyowa Hakko Kirin Co., Ltd |
Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
|
|
JPWO2003084569A1
(ja)
|
2002-04-09 |
2005-08-11 |
協和醗酵工業株式会社 |
抗体組成物含有医薬
|
|
US20040132140A1
(en)
|
2002-04-09 |
2004-07-08 |
Kyowa Hakko Kogyo Co., Ltd. |
Production process for antibody composition
|
|
US20040259150A1
(en)
|
2002-04-09 |
2004-12-23 |
Kyowa Hakko Kogyo Co., Ltd. |
Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
|
|
PL373256A1
(en)
|
2002-04-09 |
2005-08-22 |
Kyowa Hakko Kogyo Co, Ltd. |
Cells with modified genome
|
|
WO2003084570A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
|
|
KR100493460B1
(ko)
|
2002-08-29 |
2005-06-07 |
재단법인서울대학교산학협력재단 |
암 세포에서 발현되는 ｆｇｆｒ2 이성체
|
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
WO2004056312A2
(en)
|
2002-12-16 |
2004-07-08 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
|
CA2766627C
(en)
*
|
2003-05-02 |
2019-12-03 |
Xencor, Inc. |
Optimized fc variants and methods for their generation
|
|
CA2542046A1
(en)
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
Fused protein composition
|
|
WO2005035778A1
(ja)
|
2003-10-09 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
α1,6-フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法
|
|
DE602004032370D1
(de)
*
|
2003-10-16 |
2011-06-01 |
Imclone Llc |
Fibroblasten-wachstumsfaktor-1-hemmer und behandlungsverfahren dafür
|
|
ES2630224T3
(es)
|
2003-10-22 |
2017-08-18 |
Keck Graduate Institute |
Métodos para sintetizar polipéptidos heteromultiméricos en levadura con el uso de una estrategia de apareamiento haploide
|
|
RS55723B1
(sr)
|
2003-11-05 |
2017-07-31 |
Roche Glycart Ag |
Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
|
|
JPWO2005053742A1
(ja)
|
2003-12-04 |
2007-06-28 |
協和醗酵工業株式会社 |
抗体組成物を含有する医薬
|
|
US20070248605A1
(en)
|
2003-12-19 |
2007-10-25 |
Five Prime Therapetutics, Inc. |
Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention
|
|
BRPI0508761A
(pt)
|
2004-03-31 |
2007-08-14 |
Genentech Inc |
anticorpo humanizado, composição que compreende um anticorpo humanizado, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo humanizado, método de tratamento de disfunção tgf-beta, método de detecção de tgf-beta, artigo industrializado e método de tratamento de cáncer
|
|
WO2005115363A2
(en)
|
2004-05-25 |
2005-12-08 |
Yale University |
Method for treating skeletal disorders resulting from fgfr malfunction
|
|
AU2006207999A1
(en)
|
2005-01-27 |
2006-08-03 |
Five Prime Therapeutics, Inc. |
Leader sequences for directing secretion of polypeptides and methods for production thereof
|
|
MX2007009940A
(es)
*
|
2005-02-18 |
2007-10-10 |
Medarex Inc |
Anticuerpos monoclonales que carecen de residuos fucosilo contra cd30.
|
|
US7923538B2
(en)
|
2005-07-22 |
2011-04-12 |
Kyowa Hakko Kirin Co., Ltd |
Recombinant antibody composition
|
|
WO2007114896A2
(en)
|
2006-03-31 |
2007-10-11 |
Ordway Research Institute |
Prognostic and diagnostic method for cancer therapy
|
|
WO2007134210A2
(en)
|
2006-05-12 |
2007-11-22 |
Genentech, Inc. |
Methods and compositions for the diagnosis and treatment of cancer
|
|
CA2655246A1
(en)
*
|
2006-06-09 |
2007-12-21 |
University Of Maryland, Baltimore |
Glycosylation engineered antibody therapy
|
|
CA2655504A1
(en)
|
2006-06-15 |
2007-12-21 |
Fibron Ltd. |
Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
|
|
AR062223A1
(es)
*
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
|
ME02371B
(me)
|
2006-09-29 |
2016-06-20 |
Oncomed Pharm Inc |
Sastojci i postupci za dijagnstikovanje i tretman raka
|
|
EP2094733A1
(en)
|
2006-11-03 |
2009-09-02 |
U3 Pharma GmbH |
Fgfr4 antibodies
|
|
AR063975A1
(es)
|
2006-11-28 |
2009-03-04 |
Centelion |
Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada
|
|
AR064464A1
(es)
|
2006-12-22 |
2009-04-01 |
Genentech Inc |
Anticuerpos anti - receptor del factor de crecimiento insulinico
|
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
|
ES2538990T3
(es)
|
2007-01-24 |
2015-06-25 |
Kyowa Hakko Kirin Co., Ltd. |
Composición de anticuerpo genéticamente recombinante que tiene una actividad efectora mejorada
|
|
ES2600882T3
(es)
|
2007-03-23 |
2017-02-13 |
The Translational Genomics Research Institute |
Procedimiento de clasificación del cáncer de endometrio
|
|
CA2682382A1
(en)
*
|
2007-03-28 |
2008-10-09 |
Biogen Idec Inc. |
Non-fucosylated antibodies
|
|
US20110091473A1
(en)
|
2007-10-22 |
2011-04-21 |
Genmab A/S |
Novel antibody therapies
|
|
US9260525B2
(en)
|
2008-02-04 |
2016-02-16 |
Xiao-Jia Chang |
Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
|
|
WO2009100105A2
(en)
|
2008-02-04 |
2009-08-13 |
Attogen Inc. |
Inhibitors of oncogenic isoforms and uses thereof
|
|
WO2012021841A2
(en)
|
2010-08-12 |
2012-02-16 |
Attogen Inc. |
Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
|
|
US8688158B2
(en)
|
2008-03-26 |
2014-04-01 |
Nec Corporation |
Radio resource control method, radio station apparatus, recording medium storing radio station control program, and radio communication system
|
|
CA2727247A1
(en)
*
|
2008-06-10 |
2009-12-17 |
University Of Southern California |
Thymidylate synthase haplotype is associated with tumor recurrence in stage ii and stage iii colon cancer patients
|
|
EP2177615A1
(en)
|
2008-10-10 |
2010-04-21 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
|
|
JP5627591B2
(ja)
*
|
2008-11-07 |
2014-11-19 |
ギャラクシー バイオテック， エルエルシー |
線維芽増殖因子受容体２に対するモノクローナル抗体
|
|
US20120301482A1
(en)
|
2009-08-25 |
2012-11-29 |
National Jewish Health |
Methods and compositions for treatment of lung injury
|
|
BR112012007760A2
(pt)
*
|
2009-10-07 |
2015-08-25 |
Macrogenics Inc |
Método de atenuar fucosilação pós translacional de uma região fc de igc humana, anticorpo que se liga especificamente a um antigeno de câncer caracteristico de um cancêr polipeptideo
|
|
US8664365B2
(en)
*
|
2009-10-14 |
2014-03-04 |
Kalobios Pharmaceuticals, Inc. |
Antibodies to EphA3
|
|
CN102762221A
(zh)
|
2010-01-14 |
2012-10-31 |
耶鲁大学 |
受体酪氨酸激酶(rtk)的抑制剂及其使用方法
|
|
US9140689B2
(en)
|
2010-03-14 |
2015-09-22 |
Translational Genomics Research Institute |
Methods of determining susceptibility of tumors to tyrosine kinase inhibitors
|
|
CA2800311A1
(en)
*
|
2010-05-11 |
2011-11-17 |
Aveo Pharmaceuticals, Inc. |
Anti-fgfr2 antibodies
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
US20120258496A1
(en)
*
|
2010-09-27 |
2012-10-11 |
Boehringer Ingelheim International Gmbh |
Production of low fucose antibodies in h4-ii-e rat cells
|
|
WO2012045085A1
(en)
*
|
2010-10-01 |
2012-04-05 |
Oxford Biotherapeutics Ltd. |
Anti-rori antibodies
|
|
DK2714738T3
(en)
|
2011-05-24 |
2019-01-28 |
Zyngenia Inc |
MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
|
|
AR088941A1
(es)
|
2011-11-23 |
2014-07-16 |
Bayer Ip Gmbh |
Anticuerpos anti-fgfr2 y sus usos
|
|
JP2015505850A
(ja)
|
2011-12-14 |
2015-02-26 |
シアトル ジェネティックス， インコーポレイテッド |
新規な抗体薬物コンジュゲート（ａｄｃ）およびそれらの使用
|
|
PL2831110T3
(pl)
*
|
2012-03-30 |
2018-11-30 |
The Regents Of The University Of California |
Terapia anty-EMP2 zmniejsza ilość rakowych komórek macierzystych
|
|
JP6188681B2
(ja)
|
2012-04-09 |
2017-08-30 |
第一三共株式会社 |
抗ｆｇｆｒ２抗体
|
|
US9254288B2
(en)
|
2012-05-07 |
2016-02-09 |
The Translational Genomics Research Institute |
Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
|
|
EA037351B8
(ru)
|
2012-05-15 |
2021-04-29 |
Бристол-Майерс Сквибб Компани |
Способ лечения злокачественных опухолей с использованием комбинации антител против pd-1 и ctla-4
|
|
CN104619840A
(zh)
|
2012-07-05 |
2015-05-13 |
日本国立癌症研究中心 |
Fgfr2融合基因
|
|
WO2014089193A1
(en)
|
2012-12-04 |
2014-06-12 |
Aveo Pharmaceuticals, Inc. |
Anti-fgfr2 antibodies
|
|
US10980804B2
(en)
|
2013-01-18 |
2021-04-20 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
US9415118B2
(en)
|
2013-03-13 |
2016-08-16 |
Novartis Ag |
Antibody drug conjugates
|
|
BR112015027607A8
(pt)
|
2013-05-01 |
2018-01-23 |
Five Prime Therapeutics Inc |
métodos de tratamento de câncer de mama, de câncer da próstata, de câncer carcinoide, de câncer do ovário e de câncer do pulmão em pacientes.
|
|
EP3008210B1
(en)
|
2013-06-13 |
2020-10-07 |
University Of South Australia |
Methods for detecting prostate cancer
|
|
NZ715201A
(en)
|
2013-08-01 |
2021-12-24 |
Five Prime Therapeutics Inc |
Afucosylated anti-fgfr2iiib antibodies
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
AU2015210886A1
(en)
|
2014-01-29 |
2016-09-01 |
Caris Mpi, Inc. |
Molecular profiling of immune modulators
|
|
MX2017003478A
(es)
|
2014-11-05 |
2018-02-01 |
Genentech Inc |
Anticuerpos anti-fgfr2/3 y metodos para su uso.
|
|
WO2016100882A1
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Combination therapies
|
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|
|
CA3004794A1
(en)
|
2015-11-23 |
2017-06-01 |
Five Prime Therapeutics, Inc. |
Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
|
|
SG10202112636SA
(en)
|
2017-05-16 |
2021-12-30 |
Five Prime Therapeutics Inc |
Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
|